MedTrace Logo

Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis

NCT03044223 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-01-17

No results posted yet for this study

Summary

The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.

Conditions

  • Pseudomonas Infections
  • Pseudomonas Septicemia
  • Pseudomonas; Pneumonia
  • Pseudomonal Bacteraemia
  • Pseudomonas Urinary Tract Infection
  • Pseudomonas Gastrointestinal Tract Infection
  • Sepsis
  • Sepsis, Severe
  • Critically Ill

Sponsors & Collaborators

  • University of Ulm

    lead OTHER

Principal Investigators

  • Manfred Weiss, MD, MBA · University Ulm, University Hospital Ulm

  • Anne Sedlag, Biochemist · University Ulm, Institute of Microbiology and Biotechnology

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2025-11-30
Completion
2026-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03044223 on ClinicalTrials.gov